The role of combination chemotherapy regimens in the management of @entity43 @entity1 with @entity5 resistant to @entity902 compounds has not yet been defined. This multicenter prospective phase II study evaluated the activity and @entity137 of the @entity1205 -plus- @entity2600 combination in @entity43 @entity1 whose @entity5 were resistant to @entity902 compounds and who had been exposed to @entity1311 . Treatment consisted of @entity1205 60 mg/m2 i.v. followed by @entity2600 200 mg/m2 i.v. both on day 1 followed by prophylactic recombinant @entity1 @entity1261 (rhG-CSF) support from days 2 to 6, every 3 weeks. Thirty-one @entity1 were enrolled in the study. The median age was 60 years, and the median performance status (ECOG) was 1. Eight (26%) @entity1 had @entity5 resistant to @entity902 , while the rest of the population had @entity5 recurrence within 6 months from the last @entity900 treatment. Four chemotherapy cycles per @entity1 were administered, with the delivered dose intensity at 75% of the planned dose for both agents. Among 30 @entity1 evaluable for response, there were 2 (7%) complete and 4 (14%) partial responses (overall response rate 20%; (95% confidence interval, CI, 11%-33%). Stable disease was recorded in 8 (28%) @entity1 and progressive disease in 15 (51%). The median response duration was 4.5 months (range, 3-12), the median time to progression 5 months (range, 2-17) and the median survival 11 months (range, 1-40); the 1-year survival was almost 50%. Myelotoxicity was moderate, with grade 3 and 4 @entity1398 occurring in 23% of the @entity1 , grade 3-4 @entity882 in 6% and @entity1398 in 13%. Grade 3 @entity294 was observed in 2% of the @entity1 . There was one treatment-related @entity204 due to sepsis. In conclusion, the combination of @entity1205 plus @entity2600 with rhG-CSF support, appears to be a moderately effective regimen with acceptable @entity137 for @entity902 -resistant, @entity1311 -pretreated @entity43 @entity1 . Further investigation in comparative studies is required to define the role of combination versus single agent chemotherapy in this group of @entity1 .

@entity1205 in combination with XXXX ( @entity2600 ) in @entity902 -resistant @entity1311 -pretreated @entity43 .

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'human', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte-colony stimulating factor'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'tumors'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity2600 :: (MESH:C051890,Chemical) :: ['irinotecan']
